Request a Demo
On July 11, 2024, the Thai Food and Drug Administration (Thai FDA) launched a public consultation on the newly proposed amendments to the country's cosmetic ingredient lists, which involves the addition of 56 prohibited ingredient and one restricted ingredient, along with revision to another restricted ingredient. These changes aim to be in line with the updates to the ASEAN Cosmetic Directive adopted at the 36th, 37th, and 38th ASEAN Cosmetic Scientific Body (ACSB) meeting.
The consultation period will end on July 25, 2024. Stakeholders are encouraged to provide feedback before that. Once adopted, the changes will take effect upon publication in the Government Gazette. A grace period of 180 days will be granted to cosmetic stakeholders who have already manufactured, imported, or sold products containing the 56 prohibited ingredients and the revised restricted ingredient prior to the official announcement.
Below are the details of the proposed amendments (the text in red indicates changes to the previous lists):
1. Adding 56 prohibited ingredients to the List of Prohibited Ingredients.
Ref No. | Newly Included Prohibited Ingredients (draft) | CAS No. |
1613 | Octamethylcyclotetrasiloxane; D4 | 556-67-2 |
1614 | Sodium perborate [1]; Sodium peroxometaborate; sodium peroxoborate [2] | 15120-21-5 [1] 7632-04-4 [2] 10332-33-9 [2] |
1615 | Perboric acid (H3BO2(O2)), monosodium salt trihydrate [1]; Perboric acid, sodium salt, tetrahydrate [2]; Perboric acid (HBO(O2)), sodium salt, tetrahydrate sodium peroxoborate hexahydrate [3] | 13517-20-9 [1] 37244-98-7 [2] 10486-00-7 [3] |
1616 | Perboric acid, sodium salt [1]; Perboric acid, sodium salt, monohydrate [2]; Perboric acid (HBO(O2)), sodium salt, monohydrate [3] | 11138-47-9 [1] 12040-72-1 [2] 10332-33-9 [3] |
1617 | Nickel diformate [1]; Formic acid, nickel salt [2]; Formic acid, copper nickel salt [3] | 3349-06-2 [1] 15843-02-4 [2] 68134-59-8 [3] |
1618 | Nickel barium titanium primrose priderite; C.I. Pigment Yellow 157; C.I. 77900 | 68610-24-2 |
1619 | Nickel dichlorate [1]; Nickel dibromate [2]; Ethyl hydrogen sulfate, nickel(II) salt [3] | 67952-43-6 [1] 14550-87-9 [2] 71720-48-4 [3] |
1620 | Trisodium nitrilotriacetate | 5064-31-3 |
1621 | Cyclohexylamine | 108-91-8 |
1622 | Cobalt | 7440-48-4 |
1623 | Metaldehyde (ISO); 2,4,6,8-tetramethyl- 1,3,5,7- tetraoxacyclooctane | 108-62-3 |
1624 | Methylmercuric chloride | 115-09-3 |
1625 | Benzo[rst]pentaphene | 189-55-9 |
1626 | Dibenzo[b,def]chrysene; dibenzo[a,h]pyrene | 189-64-0 |
1627 | Ethanol, 2,2'-iminobis-, N- (C13-15-branched and linear alkyl) derivs. | 97925-95-6 |
1628 | Cyflumetofen (ISO); 2-methoxyethyl (RS)-2- (4-tertbutylphenyl)-2-cyano-3-oxo-3-(α,α,α-trifluoro- otolyl)propionate | 400882-07-7 |
1629 | Diisohexyl phthalate | 71850-09-4 |
1630 | halosulfuron-methyl (ISO); methyl 3-chloro-5-{[(4,6- dimethoxypyrimidin-2-yl) carbamoyl] sulfamoyl}-1- methyl1H-pyrazole-4- carboxylate | 100784-20-1 |
1631 | 2-methylimidazole | 693-98-1 |
1632 | Metaflumizone (ISO); (EZ)-2'-[2-(4-cyanophenyl)-1-(α,α,α - trifluoro-m- tolyl)ethylidene]-[4-(trifluoromethoxy)phenyl] carbanilohydrazide [E-isomer ≥ 90 %, Z-isomer ≤ 10 % relative content]; [1] (E)-2'-[2-(4-cyanophenyl)- 1-(α,α,α - trifluoro-m-tolyl) ethylidene]-[4-(trifluoromethoxy)phenyl] carbanilohydrazide [2] | 139968-49-3 [1] 852403-68-0 [2] |
1633 | Dibutylbis(pentane-2,4- dionato-O,O’)tin | 22673-19-4 |
1634 | Silicon carbide fibres (with diameter < 3 µm, length > 5 µm and aspect ratio ≥ 3:1) | 409-21-2; 308076-74-6 |
1635 | Tris(2-methoxyethoxy) vinylsilane; 6-(2-methoxyethoxy)- 6- vinyl-2,5,7,10-tetraoxa-6-silaundecane | 1067-53-4 |
1636 | Dioctyltin dilaurate; [1] Stannane, dioctyl-, bis (coco acyloxy) derivs. [2] | 3648-18-8 [1] 91648-39-4 [2] |
1637 | Dibenzo[def,p]chrysene; dibenzo[a,l]pyrene | 191-30-0 |
1638 | Ipconazole (ISO); (1RS,2SR,5RS;1RS,2SR,5SR)-2-(4- chlorobenzyl)-5-isopropyl-1- (1H-1,2,4-triazol-1-ylmethyl) cyclopentanol | 125225-28-7/ 115850-69-6/ 115937-89-8 |
1639 | Bis(2-(2-methoxyethoxy)ethyl)ether; tetraglyme | 143-24-8 |
1640 | Paclobutrazol (ISO); (2RS,3RS)-1-(4-chlorophenyl)-4,4- dimethyl- 2-(1H-1,2,4-triazol-1- yl)pentan-3-ol | 76738-62-0 |
1641 | 2,2-bis(bromomethyl) propane-1,3-diol | 3296-90-0 |
1642 | 2-(4-tert-butylbenzyl) propionaldehyde | 80-54-6 |
1643 | Diisooctyl phthalate | 27554-26-3 |
1644 | 2-methoxyethyl acrylate | 3121-61-7 |
1645 | Flurochloridone (ISO); 3-chloro-4-(chloromethyl)-1-[3- (trifluoromethyl)phenyl]pyrrolidin-2-one | 61213-25-0 |
1646 | 3-(difluoromethyl)-1- methyl-N-(3',4',5'-trifluorobiphenyl-2-yl) pyrazole-4-carboxamide; fluxapyroxad | 907204-31-3 |
1647 | N-(hydroxymethyl)acrylamide; methylolacrylamide; [NMA] | 924-42-5 |
1648 | 5-fluoro-1,3-dimethyl-N-[2-(4- methylpentan-2-yl) phenyl]- 1H-pyrazole- 4-carboxamide; 2'- [(RS)-1,3-dimethylbutyl]-5- fluoro-1,3-dimethylpyrazole-4-carboxanilide; penflufen | 494793-67-8 |
1649 | Iprovalicarb (ISO); isopropyl [(2S)-3- methyl-1-{[1-(4- methylphenyl)ethyl] amino}-1-oxobutan-2- yl]carbamate | 140923-17-7 |
1650 | Dichlorodioctylstannane | 3542-36-7 |
1651 | Mesotrione (ISO); 2-[4-(methylsulfonyl)- 2-nitrobenzoyl]-1,3- cyclohexanedione | 104206-82-8 |
1652 | Hymexazol (ISO); 3-hydroxy-5-methylisoxazole | 10004-44-1 |
1653 | Imiprothrin (ISO); reaction mass of: [2,4- dioxo-(2-propyn-1- yl) imidazolidin-3-yl] methyl(1R)-cis-chrysanthemate; [2,4- dioxo-(2-propyn-1-yl) imidazolidin-3-yl] methyl(1R)-transchrysanthemate | 72963-72-5 |
1654 | Bis(α,α-dimethylbenzyl) peroxide | 80-43-3 |
1655 | 6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol; [DBMC] | 119-47-1 |
1656 | Tetrafluoroethylene | 116-14-3 |
1657 | (5-chloro-2-methoxy-4-methyl-3-pyridyl)(4,5,6-trimethoxyotolyl)methanone; pyriofenone | 688046-61-9 |
1658 | (RS)-1-{1-ethyl-4-[4-mesyl-3-(2-methoxyethoxy)- otoluoyl]pyrazol-5-yloxy}ethyl methyl carbonate; tolpyralate | 1101132-67-5 |
1659 | Azamethiphos (ISO); S-[(6-chloro-2-oxooxazolo[4,5- b]pyridin3(2H)-yl)methyl] O,O-dimethyl thiophosphate | 35575-96-3 |
1660 | 3-methylpyrazole | 1453-58-3 |
1661 | N-methoxy-N-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3- (difluoromethyl)-1-methylpyrazole-4-carboxamide; pydiflumetofen | 1228284-64-7 |
1662 | N-{2-[[1,1'-bi(cyclopropyl)]-2-yl]phenyl}-3-(difluoromethyl)-1- methyl-1H-pyrazole-4-carboxamide; sedaxane | 874967-67-6 |
1663 | 4-methylpentan-2-one; isobutyl methyl ketone (MIBK) | 108-10-1 |
1664 | Dimethomorph (ISO); (E,Z)-4-(3-(4-chlorophenyl)-3-(3,4- dimethoxyphenyl)acryloyl)morpholine | 110488-70-5 |
1665 | Imazamox (ISO); (RS)-2-(4-isopropyl-4-methyl-5-oxo-2- imidazolin-2-yl)-5-methoxymethylnicotinic acid | 114311-32-9 |
1666 | Thiamethoxam (ISO); 3-(2-chloro-thiazol-5-ylmethyl)-5- methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine | 153719-23-4 |
1667 | Triticonazole (ISO); (RS)-(E)-5-(4-chlorobenzylidene)-2,2- dimethyl-1-(1H-1,2,4-triazol-1-methyl)cyclopentanol | 138182-18-0 |
1668 | Desmedipham (ISO); ethyl 3- phenylcarbamoyloxyphenylcarbamate | 13684-56-5 |
2. Revising the name of hydrogen peroxide, and add a new entry for silver zinc zeolite to the List of Restricted Ingredients.
Ref No. | Restricted Ingredients | Field of Application and/or Use | Maximum Authorized Concentration | Conditions | ||
Chemical Name | Name of Common Ingredients Glossary | CAS No. | ||||
10 | Hydrogen peroxide, and other compounds or mixtures that release hydrogen peroxide, including carbamide peroxide and zinc peroxide, with the exception of: 1) Sodium perborate; Sodium peroxometaborate; sodium peroxoborate
2) Perboric acid (H3BO2(O2)), monosodium salt trihydrate; Perboric acid, sodium salt, tetrahydrate; Perboric acid (HBO(O2)), sodium salt, tetrahydrate sodium peroxoborate hexahydrate
3) Perboric acid, sodium salt; Perboric acid, sodium salt, monohydrate; Perboric acid (HBO(O2)), sodium salt, monohydrate | Hydrogen peroxide | 7722-84-1 | Products for hair, eyebrows, mustache, and beard (except eyelashes) | 12% calculated as H2O2 present or released | - |
Skin products | 4% calculated as H2O2 present or released | - | ||||
Nail hardening products | 2% calculated as H2O2 present or released | -- | ||||
Oral products | 0.1 % calculated as H2O2 present or released | - | ||||
Tooth whitening products intended for dentists to be provided to consumers for self-use at home | 6% calculated as H2O2 present or released | 1. Manufacturers, contract manufacturers, importers, and sellers are only allowed to sell these products to dentists. They are prohibited from selling them directly to consumers for self-use at home. 2. The concentration of hydrogen peroxide shall be specified on the label. | ||||
213 | Ammonium silver zinc aluminum silicate | Silver zinc zeolite | 130328-20-0 | Foundation products (powder form) | 1% | - |
Deodorant products | 1% | - | ||||
In accordance with the updated restricted ingredient list, revisions will also be made to the List of Warnings on Labels for Cosmetics Containing Restricted Ingredients to include an entry for the newly added silver zinc zeolite. However, no specific labeling requirements will be mandated for it.
We provide full-scale global cosmetic market entry services (including cosmetic registering & filing, regulatory consultation, customized training, market research, branding strategy). Please contact us to discuss how we can help you by 
